Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
15 studies found for:    12-I-0157
Show Display Options
Rank Status Study
1 Recruiting Clinical Outcomes in Persons With HIV Acquired Early in Life
Conditions: HIV;   Childhood;   Natural History;   Cardiac;   ART
Intervention:
2 Recruiting Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
Condition: Smoking Cessation
Interventions: Drug: Placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
3 Completed
Has Results
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study
Condition: Pulmonary Embolism
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Enoxaparin overlapping with and followed by VKA
4 Recruiting A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
Condition: Heterozygous Familial Hypercholesterolemia
Interventions: Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo
5 Completed
Has Results
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study
Condition: Venous Thrombosis
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Enoxaparin followed by VKA
6 Completed
Has Results
Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
Condition: Venous Thromboembolism
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Placebo
7 Completed Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
Conditions: Migraine Without Aura;   Migraine With Aura
Interventions: Drug: Tonabersat;   Drug: Placebo
8 Recruiting The Evaluation of Bococizumab (PF-04950615) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Condition: Cardiovascular Disease
Interventions: Drug: bococizumab (PF-04950615);   Drug: Placebo
9 Recruiting This is a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
Conditions: Overactive Bladder;   Urgency Incontinence;   Urinary Bladder Overactive;   Urinary Bladder Diseases\Urologic Diseases
Interventions: Drug: Solifenacin Succinate;   Drug: Mirabegron;   Drug: Placebo
10 Recruiting The Evaluation of Bococizumab (PF-04950615) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
Condition: Cardiovascular Disease
Interventions: Drug: bococizumab (PF-04950615);   Drug: Placebo
11 Recruiting Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
Conditions: Mycoses;   Candidiasis, Invasive;   Candidemia
Interventions: Drug: Isavuconazole;   Drug: Caspofungin;   Drug: Voriconazole
12 Recruiting Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
Condition: Smoking Cessation
Interventions: Drug: placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
13 Terminated Phase III Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban;   Drug: Placebo
14 Completed XIENCE V: SPIRIT WOMEN
Conditions: Coronary Artery Stenosis;   Coronary Arteriosclerosis;   Coronary Artery Disease;   Coronary Artery Restenosis;   Total Coronary Occlusion;   Stent Thrombosis;   Vascular Disease;   Myocardial Ischemia
Intervention: Device: XIENCE V®/ XIENCE PRIME™
15 Completed
Has Results
Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers
Condition: Venous Leg Ulcer
Interventions: Device: Dermagraft(R);   Device: Profore

Indicates status has not been verified in more than two years